The Fly | SCLX

Over a week ago

Scilex files to sell 6.58M shares of common stock for holders

SCLX

Jun 2, 5:11 PM

Scilex files to sell 2.08M shares of common stock

SCLX

Jun 2, 5:11 PM

Scilex approves dividend of Semnur Pharmaceuticals shares

May 22, 1:20 PM

Datavault, Wellgistics to form DelivMeds AI via PharmacyChain license expansion

May 20, 9:16 AM

Scilex's ACEA Thera, ACEA Pharma enter definitive agreement with Phoenix Asia

May 5, 1:06 PM

Datavault to receive $120M cash contribution from Scilex

Apr 27, 5:45 PM

Datavault executes term sheet for $120M cash contribution from Scilex

Apr 27, 8:47 AM

Scilex files $500M mixed securities shelf

SCLX

Apr 16, 5:12 PM

Scilex Holding Co trading resumes

SCLX

Apr 13, 11:35 AM

Scilex Holding Co trading halted, volatility trading pause

SCLX

Apr 13, 11:15 AM

Scilex files federal lawsuit alleging unauthorized sale of Datavault shares

Mar 13, 11:26 AM

Scilex announces $20M strategic investment in Quantum Scan

SCLX

Jan 30, 9:06 AM

Scilex appoints Kasowitz LLP as litigation, IP counsel

SCLX

Jan 2, 9:02 AM

Scilex confirms Dream Bowl 2026 Meme Coin claim process

Dec 23, 9:04 AM

Scilex files to sell 500,000 shares of common stock

SCLX

Dec 16, 6:09 AM

Scilex files to sell 1.7M shares of common stock for holders

SCLX

Dec 16, 6:08 AM

Scilex announces exercise of warrants for $20.3M gross proceeds

SCLX

Nov 24, 6:18 AM

Datavault board approves distribution of Dream Bowl Draft meme coin

Nov 11, 8:34 AM

Scilex licenses Datavault's AI technology

Nov 4, 7:41 AM

Datavault announces record date of Nov. 14 for Dream Bowl Draft meme coin

Nov 3, 8:23 AM

Scilex completes first tranche of Oramed warrant repurchase

Oct 1, 9:02 AM

Scilex announces $150M strategic Bitcoin investment in Datavault

Sep 25, 3:50 PM

Scilex enters MOU with Biconomy.com to collaborate on crypto strategy

SCLX

Sep 24, 10:13 AM

Scilex signs SPA to exchange $200M of Semnur stock for $200M in Bitcoin

SCLX

Sep 23, 10:02 AM

Two new option listings and nine option delistings on September 22nd

Sep 22, 8:30 AM

Non-Opioid Pain Focus in High-Need Market: Scilex is strategically positioned in the rapidly growing non-opioid pain management sector, offering critical alternatives to addictive opioids for various pain conditions.

FDA-Approved Commercial Product (ZTlido): The company has a revenue-generating, FDA-approved product, ZTlido (lidocaine topical system), actively marketed for post-herpetic neuralgia, providing immediate market presence and validation.

Advanced Pipeline with Near-Term Launch Potential: Scilex's pipeline includes SP-102 (injectable dexamethasone) for sciatica, which has completed Phase 3 and has an NDA accepted by the FDA, representing a significant near-term commercial opportunity.

Sorrento Therapeutics Bankruptcy Impact: The ongoing Chapter 11 bankruptcy proceedings of its former parent company, Sorrento Therapeutics, creates significant uncertainty regarding SCLX's ownership structure, potential asset sales, and overall market perception, which could depress its stock value.

Limited Product Portfolio Concentration: Scilex's revenue is heavily reliant on the commercial success of its lead product, ZTlido. A decline in sales, increased competition, or failure to successfully launch new products could severely impact its financial performance.

Intense Pharmaceutical Market Competition: The pain management market is highly competitive, facing established branded products, generic alternatives, and new therapies from larger pharmaceutical companies, which could limit ZTlido's market share and pricing power.